G1 Therapeutics, Inc. provided earnings guidance for the full year 2024. For the period, the company expects to generate between $60 million and $70 million in COSELA net revenue.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.255 USD | +2.50% |
|
-11.07% | -26.23% |
06-25 | Needham Lowers Price Target on G1 Therapeutics to $6 From $12, Maintains Buy Rating | MT |
06-25 | HC Wainwright Lowers G1 Therapeutics Price Target to $3 From $9, Maintains Buy Rating | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.23% | 115M | |
+16.29% | 122B | |
+21.64% | 116B | |
+22.18% | 27.03B | |
-21.53% | 20.36B | |
-16.89% | 16.43B | |
-18.67% | 15.91B | |
-44.74% | 15.6B | |
+62.65% | 14.94B | |
+3.24% | 13.59B |
- Stock Market
- Equities
- GTHX Stock
- News G1 Therapeutics, Inc.
- G1 Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024